Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Inclusion Criteria: * Males or females aged \>/= 18 years * Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucinous or clear cell tumors) or Adenocarcinoma of the prostate * At least 1 unidimensional measurable lesion (suitable for RECIST evaluation) or for patients without measurable disease, CA 125 levels \>/= 2 times the upper limit of normal (ULN) within 3 months and confirmed within 2 weeks prior to first infusion (ovarian cancer) or PSA value \>/= 5 ng/mL (HRPC). * Progression of disease (HRPC) despite adequate androgen-inhibiting hormone therapy. * Progression of disease (Ovarian Cancer) or symptomatic relapse after previous therapy (elevated CA125 levels alone are insufficient for inclusion) WHO performance status 0 to 1 * No clinical residual neuropathy (CTCAE Grade 0 at baseline) * Adequate recovery from previous surgery, radiation, and chemotherapy (excluding alopecia) * Adequate function of major organs and systems. * Survival expectation =3 months * Histologically or cytologically proven: 1. Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucionous cell tumors or clear cell tumors that have a clear cell component of \>33%) Exclusion Criteria: * Symptomatic brain metastases requiring whole- brain irradiation * Any concomitant malignancy: the following exceptions are allowed: Non-melanoma skin cancer, Carcinoma in situ of the cervix, Malignancy with definitive treatment \>/= 5 years ago without relapse. * Diabetes mellitus (even if controlled only by special diet) * History of chronic hepatitis B or C, or known HIV infection * Seizure disorder requiring medication (such as steroids or anti-epileptics) * Inability to swallow oral medications * Prior treatment with epothilones * Concomitant use of neurotoxic drugs * Concomitant use of compounds that have potentially positive effects towards symptoms of neuropathy